India Approves Its First Dengue Vaccine — What It Means for You

For decades, India's only weapons against dengue fever were mosquito coils, repellent sprays, window nets, and public awareness campaigns. If you live in a dengue-prone city — and in India, most cities qualify — you know the anxiety of every monsoon season. That is now beginning to change.

India's drug regulator's expert panel, the Subject Expert Committee (SEC) on Vaccines under the Central Drugs Standard Control Organisation (CDSCO), has recommended granting import permission for Takeda's Dengue Tetravalent Vaccine (TDV), commonly known as Qdenga, for individuals aged 4 to 60 years The South First — making it the first dengue vaccine to receive regulatory clearance in India.

This is not a small milestone. It marks India's shift from a purely reactive approach to dengue management — treating patients after infection — to a preventive public health strategy.

What Is Dengue and Why Is It Such a Big Problem in India?

Dengue is a viral infection transmitted by the Aedes aegypti mosquito. It causes high fever, severe headache, body aches, rashes, and in serious cases — dengue hemorrhagic fever — can be life-threatening and require hospitalisation.

According to government data, dengue cases have steadily increased over the past few years. While around 44,000 cases were reported in 2020, this number exceeded 230,000 in 2023 and 2024. Dailyhunt Experts believe actual numbers are far higher since many mild cases go unreported and undiagnosed.

There are four dengue virus serotypes — DENV-1, DENV-2, DENV-3, and DENV-4. In India, all four circulate simultaneously, which makes dengue control particularly complex. A person can be infected by each serotype separately, and a second infection from a different serotype is often more severe than the first.

You can search medicines used in dengue supportive care — including paracetamol formulations — on SearchMyMed to understand what is typically prescribed during dengue treatment.

What Is Qdenga (TAK-003)?

Qdenga (TAK-003) is a tetravalent dengue vaccine developed by Japanese pharmaceutical company Takeda, designed to provide protection against all four serotypes of the dengue virus (DENV-1 to DENV-4). It has been evaluated in large global trials involving more than 28,000 participants and has already been approved in more than 40 countries. Utkarsh

A key advantage of Qdenga over the world's first dengue vaccine, Dengvaxia, is that it does not require pre-vaccination screening for prior dengue exposure. Dengvaxia could worsen disease in people who had never previously had dengue, requiring a blood test before administration. Qdenga removes this barrier, making mass vaccination programmes significantly more practical.

The SEC noted that the vaccine is WHO pre-qualified and that approximately 24.4 million doses have been distributed globally since launch. The South First

How Is It Given?

Qdenga is administered as two doses, three months apart, given as a subcutaneous (under the skin) injection. The approved age range in India — 4 to 60 years — is notably broader than the EU approval and aligns with the scale of India's dengue burden.

How Effective Is It?

Qdenga's effectiveness is not uniform across all four serotypes:

• DENV-2: Highest protection — this is the serotype on which the vaccine's genetic backbone is based
• DENV-1: Good protection
• DENV-3 and DENV-4: Lower effectiveness, particularly in people who have never previously had dengue
   

This is important for India because all four serotypes are present, and DENV-3 is increasing, contributing around 20–30% of cases in some regions. This may reduce the vaccine's overall effectiveness at the population level. 

Despite these limitations, the vaccine demonstrates strong protection against severe dengue and hospitalisation — which are the outcomes that matter most clinically. Even a moderate reduction in severe cases can meaningfully reduce the pressure on India's hospital system during peak dengue season.

Who Should Consider Getting the Vaccine?

Based on current guidance, Qdenga is recommended for:

• Children aged 4 years and above living in high dengue transmission areas
• Adults up to 60 years in dengue-endemic cities and regions
• Families with a history of severe dengue
• People who travel frequently between dengue-endemic regions
   

The WHO's position paper on dengue vaccines recommends vaccine introduction in routine immunisation programmes in areas where high dengue transmission poses a significant public health problem, prioritising children aged 6 to 16 years.

What Does It Cost?

The full two-dose course is estimated to cost between ₹6,000 and ₹12,000, posing significant affordability and compliance challenges for rural and low-income populations. 

This cost is a major concern. Without government subsidy or inclusion in India's Universal Immunisation Programme (UIP), Qdenga will remain accessible primarily to urban, private-sector patients — missing the rural and lower-income populations who are often most affected by dengue.

Manufacturing in India — A Promising Development

In February 2024, Takeda announced a manufacturing partnership with Hyderabad-based Biological E to produce up to 50 million doses of Qdenga annually in India, with plans to scale to 100 million doses a year within the decade. 

This is significant: local manufacturing at scale could bring down costs substantially, improve supply availability, and position India as a global dengue vaccine hub.

What About India's Own Dengue Vaccine?

India's dengue vaccine pipeline is progressing rapidly and includes an indigenous vaccine named DengiAll, developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR). If approved, DengiAll could offer a more affordable domestic alternative, with potentially better tailoring to India's specific dengue serotype patterns.

Is the Vaccine Enough on Its Own?

No. Doctors and public health experts are clear on this point. The vaccine will certainly reduce the risk of dengue but cannot completely eliminate it. Preventing mosquito breeding, maintaining cleanliness, timely testing, and proper treatment are all equally important. 

The SEC has stipulated that the vaccine firm should conduct post-marketing safety and effectiveness studies in the Indian population within six months of introduction in the Indian market — a condition that reflects the regulator's intent to closely monitor real-world performance.

What Should You Do?

• Talk to your doctor about whether Qdenga is appropriate for your family given your location, age, and dengue exposure history
• Do not stop vector control measures — continue eliminating mosquito breeding sites, using repellents, and taking precautions during monsoon season
• Watch for government announcements about possible inclusion in national immunisation schedules, which could make the vaccine free or subsidised
• If you need to understand which medicines are prescribed for dengue fever management, search on SearchMyMed by salt name to compare available brands
   

For further reading, visit the CDSCO official website for regulatory updates and the WHO Dengue vaccine position paper for global guidance.